Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Factors predicting hostility in outpatients with schizophrenia: 36-month results from the SOHO study.

Ochoa S, Suarez D, Novick D, Arranz B, Roca M, Baño V, Haro JM.

J Nerv Ment Dis. 2013 Jun;201(6):464-70. doi: 10.1097/NMD.0b013e31829480b0.

PMID:
23686157
[PubMed - indexed for MEDLINE]
2.

Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia.

Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM.

Psychiatry Res. 2010 Apr 30;176(2-3):109-13. doi: 10.1016/j.psychres.2009.05.004. Epub 2010 Feb 24.

PMID:
20185182
[PubMed - indexed for MEDLINE]
3.

Medication noncompliance and substance abuse among patients with schizophrenia.

Owen RR, Fischer EP, Booth BM, Cuffel BJ.

Psychiatr Serv. 1996 Aug;47(8):853-8.

PMID:
8837158
[PubMed - indexed for MEDLINE]
4.

Characteristic hostility in schizophrenic outpatients.

Bartels SJ, Drake RE, Wallach MA, Freeman DH.

Schizophr Bull. 1991;17(1):163-71.

PMID:
2047786
[PubMed - indexed for MEDLINE]
Free Article
5.

[Cannabis and schizophrenia: demographic and clinical correlates].

Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, Lôo H, Krebs MO.

Encephale. 2003 Jan-Feb;29(1):11-7. French.

PMID:
12640322
[PubMed - indexed for MEDLINE]
6.
7.
8.

South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset.

Duke PJ, Pantelis C, Barnes TR.

Br J Psychiatry. 1994 May;164(5):630-6.

PMID:
7921713
[PubMed - indexed for MEDLINE]
9.

Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.

Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J; SOHO Study Group.

J Clin Psychiatry. 2005 Sep;66(9):1130-3.

PMID:
16187770
[PubMed - indexed for MEDLINE]
10.

Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up.

de Haan L, van Amelsvoort T, Dingemans P, Linszen D.

Pharmacopsychiatry. 2007 Nov;40(6):264-8.

PMID:
18030650
[PubMed - indexed for MEDLINE]
11.

Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.

Gasquet I, Haro JM, Novick D, Edgell ET, Kennedy L, Lepine JP; SOHO Study Group.

Int Clin Psychopharmacol. 2005 Jul;20(4):199-205.

PMID:
15933480
[PubMed - indexed for MEDLINE]
12.

A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: changes in psychiatric symptoms and substance use.

Margolese HC, Carlos Negrete J, Tempier R, Gill K.

Schizophr Res. 2006 Mar;83(1):65-75. Epub 2006 Feb 7.

PMID:
16460917
[PubMed - indexed for MEDLINE]
13.

[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].

István S, Agoston T, Tamás T, Zoltán J.

Neuropsychopharmacol Hung. 2007 Oct;9(3):115-24. Hungarian.

PMID:
18399029
[PubMed - indexed for MEDLINE]
Free Article
14.

Predictors of subjective and objective quality of life in outpatients with schizophrenia.

Yamauchi K, Aki H, Tomotake M, Iga J, Numata S, Motoki I, Izaki Y, Tayoshi S, Kinouchi S, Sumitani S, Tayoshi S, Takikawa Y, Kaneda Y, Taniguchi T, Ishimoto Y, Ueno S, Ohmori T.

Psychiatry Clin Neurosci. 2008 Aug;62(4):404-11. doi: 10.1111/j.1440-1819.2008.01818.x.

PMID:
18778437
[PubMed - indexed for MEDLINE]
15.

The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.

de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, Tollefson GD.

Eur Arch Psychiatry Clin Neurosci. 2004 Dec;254(6):356-61. Epub 2004 Nov 12.

PMID:
15538607
[PubMed - indexed for MEDLINE]
16.

Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study.

San L, Ciudad A, Alvarez E, Bobes J, Gilaberte I.

Eur Psychiatry. 2007 Nov;22(8):490-8. Epub 2007 Sep 27.

PMID:
17904337
[PubMed - indexed for MEDLINE]
17.

Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders.

Brunette MF, Noordsy DL, Xie H, Drake RE.

Psychiatr Serv. 2003 Oct;54(10):1395-401.

PMID:
14557527
[PubMed - indexed for MEDLINE]
18.

Double jeopardy: schizophrenia and substance use.

Swofford CD, Scheller-Gilkey G, Miller AH, Woolwine B, Mance R.

Am J Drug Alcohol Abuse. 2000 Aug;26(3):343-53.

PMID:
10976661
[PubMed - indexed for MEDLINE]
19.

Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.

Mueser KT, Yarnold PR, Levinson DF, Singh H, Bellack AS, Kee K, Morrison RL, Yadalam KG.

Schizophr Bull. 1990;16(1):31-56.

PMID:
2333480
[PubMed - indexed for MEDLINE]
Free Article
20.

Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.

Novick D, Haro JM, Bertsch J, Haddad PM.

J Clin Psychopharmacol. 2010 Oct;30(5):531-40. doi: 10.1097/JCP.0b013e3181f14098.

PMID:
20814320
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk